Overview

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-02
Target enrollment:
Participant gender:
Summary
A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel